Teplizumab：FDA 批准的药物，是治疗 1 型糖尿病的里程碑

International Journal of Scientific Reports Pub Date : 2023-12-22 DOI:10.18203/issn.2454-2156.intjscirep20233870

Sameen Mukhtar, Muhammad Haris

{"title":"Teplizumab：FDA 批准的药物，是治疗 1 型糖尿病的里程碑","authors":"Sameen Mukhtar, Muhammad Haris","doi":"10.18203/issn.2454-2156.intjscirep20233870","DOIUrl":null,"url":null,"abstract":"Diabetes type-1 is a chronic disease characterized by immune-mediated destruction of insulin-producing beta cells in the pancreas. It progresses through distinct stages at varying rates, with stage 1 being β-cell autoimmunity with normal blood sugar, stage 2 being β-cell autoimmunity with dysglycemia, and stage 3 being symptomatic disease onset.","PeriodicalId":14297,"journal":{"name":"International Journal of Scientific Reports","volume":"77 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Teplizumab: an FDA- approved drug, marks milestone in treatment of type 1 diabetes\",\"authors\":\"Sameen Mukhtar, Muhammad Haris\",\"doi\":\"10.18203/issn.2454-2156.intjscirep20233870\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes type-1 is a chronic disease characterized by immune-mediated destruction of insulin-producing beta cells in the pancreas. It progresses through distinct stages at varying rates, with stage 1 being β-cell autoimmunity with normal blood sugar, stage 2 being β-cell autoimmunity with dysglycemia, and stage 3 being symptomatic disease onset.\",\"PeriodicalId\":14297,\"journal\":{\"name\":\"International Journal of Scientific Reports\",\"volume\":\"77 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Scientific Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/issn.2454-2156.intjscirep20233870\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Scientific Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2454-2156.intjscirep20233870","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

1 型糖尿病是一种慢性疾病，其特征是免疫介导的对胰腺中产生胰岛素的 β 细胞的破坏。它以不同的速度经历不同的阶段，第一阶段是β细胞自身免疫，血糖正常；第二阶段是β细胞自身免疫，血糖异常；第三阶段是无症状发病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Teplizumab: an FDA- approved drug, marks milestone in treatment of type 1 diabetes

Diabetes type-1 is a chronic disease characterized by immune-mediated destruction of insulin-producing beta cells in the pancreas. It progresses through distinct stages at varying rates, with stage 1 being β-cell autoimmunity with normal blood sugar, stage 2 being β-cell autoimmunity with dysglycemia, and stage 3 being symptomatic disease onset.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Scientific Reports

自引率

0.00%

发文量